Spectrum's Apaziquone: Can Two Failed Studies Lead To An Approval?
Executive Summary
Spectrum says 6% reduction in bladder cancer recurrence is clinically meaningful even though studies failed their primary endpoint; FDA advisory committee also will weigh issues of data pooling and timing of drug administration.